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ABSTRACT: The effects of an inspiratory manoeuvre preceding forced expiration on
functional tests performed under routine conditions before and after inhalation of a
bronchodilator drug (salbutamol) were assessed on 150 consecutive chronic obstructive
pulmonary disease outpatients. The patients performed forced vital capacity mano-
euvres either immediately after a rapid inspiration (manoeuvre no. 1) or after a slow
inspiration with a 4–6 s pause (manoeuvre no. 2).
Under baseline conditions, forced expiratory volume in one second (FEV1) values
were 8% (% control) larger with manoeuvre no. 1 than no. 2. FEV1 values increased with
salbutamol administration byy8% and were, on average, still 7% larger with mano-
euvre no. 1 than no. 2. The incidence of reversibility, assessed according to American
Thoracic Society criteria, was 76% when manoeuvre no. 2 was selected to represent
baseline conditions and manoeuvre no. 1 was chosen to represent the effects of
bronchodilator administration, whereas the lowest incidence (2%) was found when
manoeuvre no. 1 was selected to represent baseline conditions and manoeuvre no. 2 was
chosen to represent the effects of bronchodilator administration.
These results indicate that the time dependence of the forced vital capacity
manoeuvre has an important impact on the assessment of routine lung function in a
clinical setting and supports the notion that the time course of the inspiration preceding
the forced vital capacity manoeuvre should be standardised.
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The forced vital capacity (FVC) manoeuvre is the
most common ventilatory function test in clinical
practice and is used both as a screening test and as a
test to diagnose and follow-up pulmonary and extra-
pulmonary respiratory diseases. In particular, the
forced expiratory volume in one second (FEV1) is
considered to be the most reproducible respiratory
function test. The procedure of FVC measurement
and its reproducibility have been described in detail
previously [1–3]. In the early 1990s, D9ANGELO and
coworkers [4, 5] showed that FEV1, peak expiratory
flow (PEF) and the forced expiratory flow at 25, 50
and 75% of FVC both in healthy subjects and in
chronic obstructive pulmonary disease (COPD)
patients, are affected by the speed of the inspiration
and duration of the end-inspiratory pause before the
forced expiration. In particular, FEV1 was found to
be, on average, 5 and 8% higher in healthy subjects
and COPD patients, respectively, when FVC was
performed immediately after a rapid inspiration rather
than a slow inspiration with an end-inspiratory pause
of 4–6 s. Therefore, the suggestion was made that a
more precise standardisation of the FVC manoeuvre
was required.
The purpose of the present study was to assess how
the execution of the FVC manoeuvre could affect
functional tests performed in everyday clinical prac-
tice (i.e. under routine conditions) and to verify the
reproducibility of previous results obtained in a small
number of COPD subjects after pharmacological
bronchodilation with an inhalatory b2-agonist [6] on
a larger COPD population.
Methods
A total of 150 consecutive caucasian COPD out-
patients, referred to the Respiratory Unit, San Paolo
Hospital, Milan, Italy, whomet the American Thoracic
Society (ATS) criteria for COPD diagnosis and care
[7], were recruited. The sample comprised 123 males
and 27 females aged 66¡7 yrs, of whom 22% were still
smokers. Informed consent was obtained from all pati-
ents. No information was provided about the specific
purpose of the study.
A constant-volume body plethysmograph (Master-
Screen Body; Jaeger GmBH, Hoechberg, Germany)
was used to measure FVC, FEV1, forced expiratory flow
(FEFs) and maximum mid-expiratory flow (MMEF),
which were corrected for body temperature and ambient
pressure and saturatedwithwater vapour. The plethysmo-
graph was equipped with a flow generator, to calibrate
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the Fleisch pneumotachograph, and a 30–50 mL syringe
to calibrate box pressure [8–10]. Mean group antropo-
metric and routine pulmonary function data are reported
in table 1. The predicted values for lung volumes and
flows are taken from QUANJER [11].
Methods
Each patient was requested to discontinue all broncho-
dilating medications starting from at least 24 h before
execution of the test [12–14]. All subjects performed
two types of manoeuvres: no. 1) forced expirations
were performed after a rapid inspiration without an
end-inspiratory pause; and no. 2) FVC manoeuvres
were performed after a slow inspiration with an end-
inspiratory pause lasting 4–6 s. No instructions were
given by the experimenter during the performance of
the manoeuvres except for urging the subjects to con-
tinue to exhale as long as possible. All manoeuvres
were initiated from resting end-expiratory lung volume
and were performed in a random order at a com-
fortable frequency of one every 3–4 min. A number of
factors were considered in order to minimise inter-
manoeuvre variations as follows: 1) the neck was main-
tained fixed in a neutral position [15]; 2) the expiratory
duration was kept similar in the various tests; and 3)
all manoeuvres were recorded at similar times during
the day. FVC manoeuvres were executed both under
baseline conditions and 20 min after the inhalation of
200 mcg of salbutamol [16, 17], administered with a
suitable device (Fluspacer1; Menarini S.r.l., Florence,
Italy). All recorded manoeuvres were divided into four
groups: manoeuvre no. 1 under baseline conditions
(no. 1B); manoeuvre no. 2 under baseline conditions
(no. 2B); manoeuvre no. 1 after bronchodilation (no. 1A);
and manoeuvre no. 2 after bronchodilation (no. 2A).
A total of 1,800 tests, out of 2,356 tests, met recog-
nised acceptability and reproducibility criteria [3, 18],
and three tests were selected for each patient and
group.
Analysis
For each group (no. 1B, no. 1A, no. 2B and no. 2A),
the highest value of FEV1, and the values of MMEF
and FEF25, FEF50 and FEF75 pertaining to the
manoeuvre with the largest value of FEV1zFVC were
chosen for the aggregate analysis of all 150 patients
[19]. For the assessment of intrapatient differences,
the mean of the three tests in each group was used.
Data are presented as means¡SD. Comparisons among
experimental conditions were performed using one-
way analysis of variance (ANOVA). When significant
differences were found, the Bonferroni9s correction
was introduced to determine significant differences
between different experimental conditions. The level
of statistical significance was taken at pf0.05 [20].
Results
Under baseline conditions, all patients exhibited
higher FEV1 values with manoeuvre no. 1 than no. 2
(table 2): on average, the increase of FEV1 was 114¡
54 mL or 9.1¡4.9%. Relative to predicted FEV1
values, this increase amounted to 4.3¡2.1%. Similarly,
all FEF values were significantly higher with manoeu-
vre no. 1 than no. 2 (table 2). On an individual basis,
FEF25 was larger with manoeuvre no. 1 in 138 patients,
FEF50 and FEF75 in 137 patients and MMEF in all
patients.
After bronchodilator administration, all patients
still exhibited higher FEV1, FEFs and MMEF values
with manoeuvre no. 1 than no. 2 (table 2). On average,
the increase of FEV1 was 114¡58 mL or 8.7¡6.6%.
Relative to predicted FEV1 values, this increase
amounted to 4.2¡2.2%. On an individual basis,
FEF25 and FEF75 were larger with manoeuvre no. 1
in 145 patients, FEF50 in 148 patients and MMEF in
141 patients.
The incidence of reversibility, assessed according to
Table 1. – Anthropometric and routine lung function data





FEV1 L 1.54¡0.56 (54¡15)
FVC L 2.91¡0.61 (65.2¡16.4)
PEF L?s-1 3.05¡1.06 (38¡14)
MMEF L?s-1 0.78¡0.48 (21¡9)
TLC L 5.89¡1.54 (104¡25)
RV L 2.99¡1.01 (148¡50)
Data are presented as mean¡SD (% predicted). FEV1: forced
expiratory volume in one second; FVC: forced vital
capacity; PEF: peak expiratory flow; MMEF: maximum
midexpiratory flow; TLC: total lung capacity; RV: residual
volume.
Table 2. – Forced expiratory volume in one second (FEV1), forced expiratory flows (FEFs) and maximum midexpiratory
flow (MMEF) during manoeuvres no. 1 and no. 2 under baseline conditions (B) and after bronchodilation test (A)
Manoeuvre No. 1B No. 2B Change from no. 2B No. 1A No. 2A Change from no. 2A
FEV1 L 1.5¡0.51 1.38¡0.5 9.12¡4.93 1.61¡0.53 1.5¡0.51 8.72¡6.64
FEF25 L?s-1 2.37¡2.01 1.92¡1.73 25.75¡21.18 3.04¡2.46 2.44¡2.01 25.55¡20.81
FEF50 L?s-1 0.96¡0.75 0.83¡0.7 17.03¡15.57 1.25¡1.02 1.09¡0.92 16.59¡12.32
FEF75 L?s-1 0.31¡0.22 0.27¡0.18 17.79¡11.93 0.4¡0.31 0.34¡0.25 17.22¡13.97
MMEF L?s-1 0.75¡0.51 0.63¡0.44 19.37¡11.19 0.93¡0.63 0.8¡0.57 18.99¡11.45
Data are presented as mean¡SD. All changes from manoeuvre no. 2 are significant (pv0.001).
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ATS standards [3], depended on the combination of
FVC manoeuvres used for this evaluation. The largest
incidence of reversible patients (76%) occurred when
manoeuvre no. 2 was selected to represent baseline
conditions and FEV1 with manoeuvre no. 1 was chosen
to represent the effects of bronchodilator administra-
tion, i.e. (no. 1A–no. 2B)/no. 2B, whereas the lowest
incidence (2%) was found when manoeuvre no. 1 was
selected to represent baseline conditions and FEV1 with
manoeuvre no. 2 was chosen to represent the effects of
bronchodilator administration, i.e. (no. 2A-no. 1B)/
no. 1B. Conversely, intermediate and essentially similar
values of the incidence of reversibility were found
when the data obtained with the same type of FVC
manoeuvre before and after bronchodilator adminis-
tration were used for the computation. The index of
reversibility was larger and similar for both (no. 1A-
no. 2B)/no. 2B and (no. 1A-no. 1B)/no. 1B, intermedi-
ate for (no. 2A-no. 2B)/no. 2B and lower for the last
combination.
Discussion
In this study the authors focused on assessment of
FEV1 and FEFs under baseline conditions and after
bronchodilation test, as they are the main functional
parameters used in clinical practice. The values of
FEV1, FEFs and MMEF were found to be system-
atically higher with manoeuvre no. 1 than no. 2 and
these differences persisted after administration of an
inhalatory b2-agonist (table 2). These results, when
compared to those obtained in the laboratory on
normal subjects and COPD patients [4, 5], indicate
that the dependence of maximal flow volume curves
on the volume-time course preceding the FVC
manoeuvre manifests itself in a similar manner in
the clinical setting under routine conditions.
Several mechanisms could be responsible for the
higher maximal expiratory flows during manoeuvre
no. 1 than manoeuvre no. 2, both in normal subjects
and COPD patients [5]. The fact that the relative
change in FEV1, as well as in FEFs and MMEF,
between manoeuvres no. 1 and no. 2 was essentially the
same under baseline conditions and after salbutamol
administration (table 2) suggests that the time depen-
dence of these parameters is not related to time
constant inequality or the balance between airway and
lung tissue hysteresis, which are expected to change
with changes the bronchomotor tone. Reduced expira-
tory effort and dependent volume compression arte-
facts are also unlikely explanations for the lower flows
observed with manoeuvre no. 2. Indeed, it has been
shown that even substantial differences in apparently
maximal voluntary expiratory efforts play little or no
role in COPD patients [5] and time dependency of
FVC manoeuvres is also observed when lung volume
changes are assessed plethysmographically [4, 5]. The
present results, in line with previous findings [4, 6],
suggest that loss of elastic recoil during breath-holding
at full inspiration, i.e. stress relaxation, could be the
main cause of reduced FEV1, FEFs and MMEF with
manoeuvre no. 2. As a result of tissue viscoelastic
properties, larger elastic recoil pressures of both lung
and chest wall must in fact develop after a rapid
inspiration with no end-inspiratory pause; this would
provide greater driving pressures, lower airway resis-
tance and hence higher flows during the subsequent
expiratory effort.
According to ATS recommended criteria for the
response to bronchodilator drugs [7], a 12% increase













































































































Fig. 1. –Differences between forced expiratory volume (FEV1)
after (A) and before (B) bronchodilator administration expressed
as percentage of baseline value (DFEV1/FEV1) as a function of
baseline values expressed as % predicted for three combinations of
pre- and postbronchodilator FEV1 values: a) (no. 1A–no. 2B)/
no. 2B; b) (no. 2A–no. 2B)/no. 2B; and c) (no. 1A–no. 1B)/no. 1B.
?????: values below which patients are classified as nonresponders
to bronchodilator drugs according to the American Thoracic
Society criteria [8]; ––: values below which patients are classified
as nonresponders to bronchodilator drugs according to the
European Respiratory Society [9] criteria.
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increase of 200 mL, is considered as a meaningful
response. With these criteria, 20% of patients would
be classified as responders based on manoeuvre no. 1
and a similar number would be obtained based on
manoeuvre no. 2 (18%). Conversely, the incidence
of reversible patients changed dramatically between
manoeuvre no. 1 and no. 2 with the other two combina-
tions; i.e. if manoeuvre no. 1 was made after broncho-
dilator administration and manoeuvre no. 2 under
baseline conditions 76% of patients could be classified
as responders, whereas with the opposite combination
the number would drop to 2%. These observations,
which are in line with those performed on a small
number of COPD and asthmatic patients in the
laboratory [5, 6], indicate that FVC manoeuvres
before and after bronchodilator administration for
the assessment of bronchodilator responsiveness must
be made under standardised conditions even in the
clinical setting under routine conditions. From a
practical point of view, it is important to note that
standardisation does not imply the choice of the type
of manoeuvre. Indeed assessment of bronchodilator
responsiveness with manoeuvre no. 1 yielded essen-
tially the same results obtained with manoeuvre no. 2.
The criteria for the response to bronchodilator
drugs recommended by the European Respiratory
Society [17] are more demanding than those indicated
by the ATS [7], especially when baseline FEV1 values
are low, as shown in figure 1. Nevertheless, the incidence
of reversibility assessed according to ERS standards
[19] was still dependent on the combination of FVC
manoeuvres used for evaluation, although the number
of patients that could be classified as responders was
substantially reducedwith combinations (no. 2A-no. 2B)/
no. 2B or (no. 1A-no. 1B)/no. 1B.
In conclusion, the present study performed on 150
chronic obstructive pulmonary disease patients has
shown that the time dependence of the forced vital
capacity manoeuvre has an important impact on the
assessment of routine lung function in the clinical
setting, and supports the notion that the time course
of the inspiration preceding the forced vital capacity
manoeuvre should be standardised. Indeed, broncho-
dilation tests performed with different manoeuvres
before and after bronchodilator administration easily
provide misleading results, overestimating a positive
response to bronchodilators if manoeuvre no. 2 is
used before and manoeuver no. 1 after drug admin-
istration, and underestimating it in the opposite case.
From a clinical perspective, this could lead to a wrong
diagnosis and improper therapy.
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